1. Executive Summary (Confidence: High)

Interpharma acts as the strategic architect for Switzerland’s pharmaceutical sector, an industry that contributes 5.4% directly to the Swiss GDP and accounts for 45% of its total exports.^[11] Through its "Vision 2030" roadmap, Interpharma is driving the transition of the Swiss healthcare system toward a digitally integrated, patient-centered, and innovation-friendly ecosystem.^[11] The association is a vocal advocate for rapid patient access to new medicines, proposing a "reimbursed access to innovation" model to ensure that patients receive authorized treatments from "Day 1".^[12] With an annual R&D investment of CHF 6.^[5] billion from its members in Switzerland alone, Interpharma is the primary force maintaining the country’s status as Europe’s leading pharma hub.^[11]